StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) stock

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$42.04−1.64 (-3.75%)

Close on Nov 17, 2026Market cap $4.57BP/E –Yield –

Edgewise Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Edgewise Therapeutics's total assets was $479.69M at Jun 30, 2026. For fiscal 2025 it was $552.60M, up 13.5% from the year before. The highest annual figure on record is $552.60M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$552.60M+13.5%
FY2024Dec 31, 2024$486.82M+43.2%
FY2023Dec 31, 2023$340.04M-7.4%
FY2022Dec 31, 2022$367.10M+28.7%
FY2021Dec 31, 2021$285.23M+117.5%
FY2020Dec 31, 2020$131.14M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$479.69M-21.8%
Q1 FY2026Mar 31, 2026$518.52M+14.1%
Q4 FY2025Dec 31, 2025$552.60M+13.5%
Q3 FY2025Sep 30, 2025$583.47M+14.1%
Q2 FY2025Jun 30, 2025$613.33M+15.4%
Q1 FY2025Mar 31, 2025$454.39M-18.0%
Q4 FY2024Dec 31, 2024$486.82M+43.2%
Q3 FY2024Sep 30, 2024$511.28M+64.2%
Q2 FY2024Jun 30, 2024$531.65M+60.8%
Q1 FY2024Mar 31, 2024$553.81M+59.9%
Q4 FY2023Dec 31, 2023$340.04M-7.4%
Q3 FY2023Sep 30, 2023$311.36M-17.4%
Q2 FY2023Jun 30, 2023$330.63M+28.4%
Q1 FY2023Mar 31, 2023$346.40M+27.0%
Q4 FY2022Dec 31, 2022$367.10M+28.7%
Q3 FY2022Sep 30, 2022$377.15M+28.1%
Q2 FY2022Jun 30, 2022$257.40M-15.2%
Q1 FY2022Mar 31, 2022$272.75M-12.4%
Q4 FY2021Dec 31, 2021$285.23M+117.5%
Q3 FY2021Sep 30, 2021$294.45M–
Q2 FY2021Jun 30, 2021$303.49M–
Q1 FY2021Mar 31, 2021$311.25M–
Q4 FY2020Dec 31, 2020$131.14M–

More Edgewise Therapeutics figures

See a number that looks wrong?